
In 2016, FAIRR initiated a three-year collaborative engagement to ask large food companies to end the nontherapeutic use of antibiotics important to human health…
Our collaborative investor engagement is supported by more than 70 institutional investors, representing $5.5 trillion in AUM. To protect public health and long-term value creation, the engagement asks 20 global food companies to limit the use of antibiotics in global supply chains. This can be achieved by:
Establishing an antibiotics policy to phase out routine, prophylactic use across all supply chains.
Specifying clear targets and timelines for implementation.
Increasing transparency by reporting on implementation and data verification.
The latest update to this engagement outlines not only how investors are stepping up their efforts to manage these risks but also, what progress has been made on the issue from both the corporate and policy communities.
The use of antibiotics in protein supply chains is a leading cause of rising antimicrobial resistance (AMR) in humans. Globally, the food industry is the largest consumer of antibiotics and often uses medicines to prevent disease or promote growth in otherwise healthy farm animals.
In a recent report showing that drug-resistant infections could cost the world around US$100 trillion in lost output by 2050, the UK government described the practice as “excessive and inappropriate”.
The misuse of antibiotics presents a systemic risk to investor portfolios and public health, and this has relevance to the food, pharmaceutical, healthcare and insurance industries.
See all the briefings that the FAIRR Initiative has released on the overuse of antibiotics in protein supply chains.
In 2016, FAIRR initiated a three-year collaborative engagement to ask large food companies to end the nontherapeutic use of antibiotics important to human health…
Outlines investment risks linked to farm antibiotic misuse, and how investors can drive improvements in the food industry.…
Antimicrobial resistance (AMR) is now globally acknowledged as a fundamental threat to public health and the global economy. The overuse and misuse of antibiotics…
The FAIRR Initiative publishes company-level analysis, which is exclusively available to our Investor Members.
The latest update was released in May 2019.